ArticleQuantitative imaging in medicine and surgery2025
Prediction of PD-L1 expression and prognosis of mass-forming intrahepatic cholangiocarcinoma based on preoperative magnetic resonance imaging.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In clinical practice, only a subset of patients with tumor respond to immune checkpoint inhibitors. Therefore, the primary challenge lies in identifying the subgroup of candidates who will derive the greatest benefit from this type of therapy. Previous studies have indicated that the positive expression of programmed cell death ligand 1 (PD-L1) in tumors is associated with treatment response. In this study, we aimed to investigate the predictive value of preoperative magnetic resonance imaging (MRI) for PD-L1 expression and the prognosis of patients with mass-forming intrahepatic cholangiocarcinoma (MICC). Methods: A total of 92 patients who were pathologically confirmed to have MICC from January 2017 to December 2018 were enrolled. Logistic regression was used to identify significant factors associated with PD-L1 expression. A predictive model for PD-L1 expression was developed, and its efficacy was evaluated via receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC). The clinical overall survival (OS) model was established based on clinical-radiologic factors via multivariate Cox regression analysis to categorize patients with MICC into high- and low-risk groups. Results: PD-L1 expression was significantly associated with enhancement patterns in the arterial phase of enhanced MR images [odds ratio (OR): 0.12; 95% confidence interval (CI): 0.04-0.37]. A predictive model for PD-L1 expression was established, with an AUC of 0.722 (95% CI: 0.632-0.811). Hepatic lobe atrophy [hazard ratio (HR): 2.036; 95% CI: 1.136-3.650], enhancement patterns (HR: 0.509; 95% CI: 0.295-0.877), lymph node metastasis (LNM) (HR: 1.715; 95% CI: 1.005-2.926), and carcinoembryonic antigen (CEA) (HR: 1.664; 95% CI: 1.007-2.750) were identified as prognostic factors for patients with MICC. The clinical OS model [concordance index (C-index): 0.875; 95% CI: 0.812-0.905] incorporating these independent predictors effectively stratified patients with MICC into high- and low-risk groups, with the 1-, 3-, and 5-year survival rates for the two groups being 56.5%, 17.4%, and 15.2%, respectively, and 89.1%, 58.7%, and 52.2%, respectively (P<0.001). Furthermore, the calibration curve of the clinical OS model demonstrated exceptional concordance between the predictions and actual observations. Conclusions: Preoperative MRI may be a noninvasive means to predicting PD-L1 expression and prognosis in patients with MICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.